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In 1979, Joshua Lederburg, recently appointed presi-
dent of Rockefeller University, was in recruiting mode.
Based on his long-term interest in the brain and psychi-
atry, Josh approached me with an attractive offer for
myself and my colleagues Joe Coyle and Mike Kuhar.
I visited our Dean, Richard Ross, to say goodbye, as
I knew that Hopkins could never provide us Rockefeller-
like resources. While Ross couldn’t match the Rockefel-
ler offer for a professor, he had an alternative proposal.
Years earlier, an advisory committee had recommended
that Hopkins establish a Department of Neuroscience.
Dr. Ross suggested a mini-department comprised
solely of myself, Coyle, and Kuhar, which might integrate
Hopkins neuroscience. In contrast to the tens of millions
of dollars provided nowadays as dowries for new de-
partmental directors, the Dean offered only a modest
annual budget that could be ‘‘saved’’ for the three years
till a single floor would become available for our depart-
ment. Dan Nathans, Director of Microbiology and a val-
ued confidant, advised that a new department must be
done ‘‘right’’ so I should ask for triple the offered space.
The Dean agreed, and on July 1, 1980, our department
commenced operations. Today, Neuroscience is the
largest basic science department at Hopkins. Our fac-
ulty has done well. Among present and emeritus mem-
bers, three of our primary faculty have been elected to
the National Academy of Sciences, four are fellows of
the Academy of Arts and Sciences, two of the American
Philosophical Society, two have received the Lasker
Award, two the National Medal of Science, and various
faculty members have accumulated more than 13 hon-
orary doctorates. Science citation analysis indicates
that of the eight most highly cited Johns Hopkins medi-
cal scientists, five are appointed in our department. For
the decade 1989–1998, four of the world’s 16 most
highly cited neuroscientists were from Hopkins, with
no other institution having more than one.
But neuroscience at Hopkins did not begin in 1980.
Johns Hopkins has a long tradition of contributions in
the field. More than most other institutions, Hopkins’ ef-
forts in the neurosciences encompass clinical as well as
basic science. Let me relate some of these in a brief pan-
orama that is not meant to be exhaustive but merely to
illustrate a few major themes, especially the breadth of
research and the uniquely collegial relationships of Hop-
kins neuroscientists.
Early Days
The founding fathers of Hopkins were giants in American
medicine, with William Welch, the first Dean, orchestrat-
*Correspondence: ssnyder@jhmi.eduing these talents and himself making major contribu-
tions to pathology. William Osler defined the field of in-
ternal medicine, and William Halstead inaugurated
modern surgery. There was no Neurology Department
nor even a neurology division of Medicine. Neurosurgery
remained a subdivision of the surgery department for al-
most 70 years till Donlin Long was appointed the direc-
tor of a new Neurosurgery Department.
Neurosurgery and Systems Neuroscience
In 1906, Harvey Cushing was appointed the first head of
neurosurgery at Hopkins (Figure 1). He revolutionized pi-
tuitary surgery and, by carefully monitoring symptoms
following removal of pituitary tumors, he was able to elu-
cidate the role of excess or deficient secretion of the an-
terior pituitary and to confirm his clinical observations
with studies in animals (Cushing, 1909). He showed
that hormonally active tumors arising in young people
lead to gigantism and, in adults, to acromegaly.
Walter Dandy succeeded Cushing as head of the neu-
rosurgery division. In 1913, he elucidated the circulation
of cerebrospinal fluid (CSF), showing how selective
blockade leads to hydrocephalus (Dandy and Blackfan,
1913). In dogs, obstructing the Sylvian Aqueduct caused
dilation of the third and lateral ventricles, while blocking
the Foramen of Monro elicited a similar ballooning of the
lateral ventricle. In the same study, he provided the first
definitive evidence that the choroid plexus elaborates
CSF, as its removal prevented hydrocephalus. He dis-
covered how CSF is absorbed into subarachnoid blood
vessels. He extended this basic research into patients,
observing that every case of ‘‘idiopathic hydrocephalus’’
was associated with obstruction of the Sylvian Aque-
duct or one of the critical foramina.
Even more important was Dandy’s development
in 1918 of pneumoencephalography, conceptualized
when he noticed in the chest X-ray of a patient with a per-
forated intestine, free air outlining the structure of vari-
ous abdominal viscera. Might injected air outline the ce-
rebral ventricles? In short-order he injected gas into the
cerebral ventricles, inaugurating pneumoencephalogra-
phy, which, until the advent of CAT scans, remained the
most powerful means of identifying brain tumors and
other abnormalities (Dandy, 1918).
Systems neuroscience began with operative ablation
of various brain regions to mimic abnormalities associ-
ated with brain tumors or surgical removal of brain tis-
sue to cope with injuries or epilepsy. Phillip Bard, the
fourth Director of Physiology at Hopkins, arrived in Bal-
timore in 1933 following training at Harvard with Walter
Cannon. Work in Cannon’s laboratory had revealed
that disconnecting the cerebral cortex from the brain-
stem of cats elicited rage responses. As these responses
were not associated with ‘‘real’’ anger and were not di-
rected toward the triggering stimulus, they were desig-
nated ‘‘sham rage.’’ At Hopkins, Bard attempted to local-
ize the specific brain regions responsible for sham rage.
After decorticating cats to elicit rage, he made various
transactions through the brain stem. Successive trans-
actions in a caudal direction failed to alter sham rage
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Directed posterior hypothalamic lesions eliminated
sham rage, while electrical stimulation in this region
caused rage. This work lead to conceptualizations of
emotional behavior determined by the limbic system of
brain structures.
Bard soon realized that behavioral observations were
insufficient to clarify brain function and that electrical
Figure 1. Johns Hopkins’ Neuroscience Greats
(A) Harvey Cushing (left), the first head of Neurosurgery, provided
the definitive characterization of hypo- and hyperpituitarism. Walter
Dandy (right), his successor, developed ventriculography, inaugu-
rating the field of clinical brain imaging.
(B) Philip Bard (left) localized brain areas mediating ‘‘rage’’ and em-
ployed evoked potentials to map sensory sites in the brain. Vernon
Mountcastle (right), using microelectrode recordings, discovered
the columnar organization of brain function.
(C) Ross Harrison (left) inaugurated the field of tissue culture using
frog embryonic spinal cord. David Bodian (right) employed culture
to differentiate diverse types of polio virus, laying the groundwork
for the polio vaccine.
(D) John Jacob Abel (left), founding Director of the Department of
Pharmacology and Experimental Therapeutics, isolated epineph-
rine as the hormone of the adrenal medulla and subsequently ob-
tained the first crystals of insulin. Curt Richter (right) delineated
systemic physiologic regulation by the biologic clock.recordings would be critical. In 1933, Ralph Gerard,
working at the University of Chicago, had identified cere-
bral action potentials, and, with Wade Marshall, he em-
ployed this approach to characterize sensory activity in
the cerebral cortex. In the late 1930s, Marshall moved
to Hopkins, and, with Bard and Clinton Woolsey, he de-
veloped technology for measuring evoked cortical po-
tentials and mapped the sites for cutaneous touch
sensation on the primate postcentral gyrus (Marshall
et al., 1937).
Vernon Mountcastle, Bard’s successor in 1964 as Di-
rector of Physiology, took up the challenge of mapping
the somatic sensory system with greater refinement. In
the mid-1950s, utilizing newly developed microelectro-
des that permitted single-cell recoding, Mountcastle
discovered that submodalities of touch and pressure
sensation were localized to vertical columns running
from the surface of the brain to underlying white matter.
All cells in an individual column responded to selective
sites on the skin and to either superficial or deep pres-
sure (Mountcastle, 1957). This columnar organization
is now appreciated as a universal organizing principle
of brain function.
At about the same time that Mountcastle was doing
his pioneering work in the Physiology Department, Ste-
phen Kuffler spent 12 years in a laboratory in the base-
ment of the Ophthalmology Department. In one body
of work, he characterized synaptic inhibition in stretch
receptor neurons of crustacea, which led to subsequent
work of his later colleagues David Potter and Edward
Kravitz establishing GABA as the principal inhibitory
neurotransmitter. Perhaps Kuffler’s most important con-
tribution was his discovery of center-surround inter-
actions in the retina (Kuffler, 1952). Utilizing a multibeam
ophthalmoscope that had been developed in the
Ophthalmology Department, he recorded from single
retinal ganglion cells and observed diametrically oppo-
site responses depending on whether light impacted
the central or peripheral field. In 1959, Kuffler moved
to Harvard where in 1966 he established a Department
of Neurobiology.
Torsten Wiesel and David Hubel joined Kuffler at Hop-
kins in the mid-1950s, initially working on the retina and
then turning their attention to the visual cortex. They dis-
covered center-surround and other organizational prin-
ciples in the cortex (Hubel and Wiesel, 1959). Most
importantly, they detected parallel receptive fields for
neighboring cells in the visual cortex, pointing to a uni-
versal role for Mountcastle’s concept of columnar orga-
nization of the cerebral cortex. They moved with Kuffler
to Harvard in 1959 where they continued their elegant
assessment of how visual information is organized in
the cortex, leading to their receipt of the Nobel Prize
for Physiology or Medicine in 1981.
Psychiatry provides the ultimate systems approach to
the brain and behavior. Adolph Meyer was the first Di-
rector of Psychiatry at Hopkins. In the Henry Phipps
Psychiatric Clinic, which opened in 1913, Meyer inaugu-
rated an unprecedented approach to psychiatry with
laboratories of neuroanatomy, neurophysiology, and
behavior and a clinical program that emphasized a com-
prehensive approach to each patient integrating psy-
chological and biological factors, an essentially new dis-
cipline that he dubbed ‘‘psychobiology’’ (Meyer, 1915).
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Watson, the founder of behaviorism. Watson did not re-
main long at Hopkins, his principal contribution being
his graduate student Curt Richter who, when Watson
left, took over the laboratory and remained in it for about
70 years.
Among his many contributions, Richter developed
precise means for monitoring all aspects of a rat’s life
in a laboratory using a cage containing a running wheel
to assess temporal aspects of activity initiation. With
this simple but elegantly powerful system, Richter ex-
plored the molecular and neuroanatomical regulation
of the ‘‘biological clock’’ (Richter, 1960). In 1965, when
I arrived at Johns Hopkins for psychiatry residency,
one of my first visits was to Richter’s laboratory. I had
worked with Julie Axelrod at the NIH on circadian
rhythms in the serotonin content of the pineal gland
and sought Richter’s advice. He showed me his experi-
ments making discrete brain lesions to localize the
clock, which he had narrowed down to a small area in
the hypothalamus. Because of his obsessive drive to
‘‘be sure’’ of his results, he did not publish these find-
ings, although his lesions, in the vicinity of the supra-
chiasmatic nucleus, anticipated the discovery years
later by Robert Moore of this nucleus as the locus of
the mammalian ‘‘clock.’’
Richter’s contributions were remarkably diverse. For
instance, he pioneered the notion that rodents will self-
select an optimal diet and, in this way, he established
the minimal daily requirement for vitamins and minerals
(Richter et al., 1938). His work on the galvanic skin
response was critical in the evolution of the lie detector
test.
W. Horsley Gantt, a contemporary of Richter’s in the
Psychiatry Department, studied with Ivan Pavlov and
was a pioneer in introducing Pavlovian psychiatry into
the United States. He utilized Pavlov’s techniques to de-
velop models of mental illness in dogs. For his contribu-
tions, he received a Lasker Award in 1946, the inaugural
year of these prizes.
Cellular, Molecular, and Pharmacologic Research
Today, most cellular-molecular neuroscience research
employs tissue culture as routine methodology. The first
successful use of tissue culture employed neurons and
was carried out at Johns Hopkins by Ross G. Harrison
(Harrison, 1907). At the time of this research in 1907,
the cellular source of neuronal fibers was not at all clear.
Harrison placed small portions of frog embryo spinal
cords in lymph on a microscope slide and was able to
observe clearcut neuronal sprouting. In 1917, the Nobel
Prize Committee voted to award the prize in Physiology
or Medicine to Harrison but ultimately did not award
a prize that year. Research underlying the Nobel Prize
in 1956 for the growth of polio virus in kidney cell cul-
tures did employ Harrison’s methodology.
Harrison’s innovations in tissue culture at Hopkins
were continued by George Gey (Gey et al., 1952). Utiliz-
ing a cervical tumor from Henrietta Lacks, Gey created
the HeLa cell line, which to this day is the most widely
employed tissue culture preparation and was particu-
larly valuable for growing the three types of polio virus.
Gey made myriad advances in tissue culture, including
the use of collagen as substratum and the roller-tubetechnique used by John Enders for his Nobel Prize-win-
ning cultivation of the polio virus.
The crucial research for growing polio virus in tissue
culture took place at Johns Hopkins in the laboratory
of David Bodian, who also employed some of Gey’s pro-
cedures. Bodian was able to differentiate nerve cells that
were resistant or sensitive to viral infection, laying the
groundwork for much polio vaccine research (Bodian,
1955). At that time, large numbers of viral strains had
been identified, but it wasn’t clear which were relevant
for vaccine development. Bodian established that there
were only three major immunologic forms of the virus,
permitting development of a practical vaccine.
Besides his work on the polio virus, Bodian, who
served as Director of the Anatomy Department, was
one of the world’s great neuroanatomists. Utilizing his
staining technique, the ‘‘Bodian Stain,’’ he identified
the existence of neurofilaments. Because of his interest
in spinal cord defects in polio, he focused on the ultra-
structure of neurons in the spinal cord and was the first
to obtain strong evidence that spherical synaptic vesi-
cles were associated with excitation and flat vesicles
with synaptic inhibition (Bodian, 1966).
John Jacob Abel founded the Department of Pharma-
cology at Hopkins. Based on his strong background in
chemistry, Abel attempted to isolate biologically active
substances. One of his first triumphs was the identifica-
tion of epinephrine as the hormone of the adrenal me-
dulla (Abel and Crawford, 1897). Much later in his career,
he obtained the first crystals of insulin, establishing its
protein nature (Abel, 1926). As with some of the other
early departmental directors at Hopkins’, Abel set
standards for the rest of the country. He regarded phar-
macology primarily as a medical discipline and so never
trained Ph.D. students, with Hopkins finally establishing
a pharmacology graduate program under my initial
direction in 1968. Abel’s national influence was evi-
dent in his founding the Journal of Pharmacology and
Experimental Therapeutics and the Journal of Biological
Chemistry.
Clinical neuropharmacology played an important role
at Hopkins. In the late 1940s, Leslie Gay, who directed
the allergy clinic, was treating a lady for hives with anti-
histamines. She mentioned that her severe motion sick-
ness evaporated when she took the new antihistamine.
Working through the auspices of Army Chief of Staff
General Omar Bradley, Gay directed the most sophisti-
cated clinical drug trial of that era, a randomized study
of 1500 soldiers on a north Atlantic trip to Europe. He
showed definitively that the antihistamine, Dramamine,
both prevented and relieved sea sickness (Gay et al.,
1949).
In 1954, Louis Lasagna, Hopkins’ first Head of Clinical
Pharmacology, discovered a novel approach to creating
less-addicting opiates. He was investigating interac-
tions in humans of opiate agonists and antagonists, spe-
cifically morphine and nalorphine. As a control, he ad-
ministered nalorphine alone and was astounded to
detect analgesic efficacy equivalent to that of morphine
(Lasagna and Beecher, 1954). Thus, nalorphine was
a mixed agonist-antagonist. Its antagonist properties
decreased addictive propensities leading to major ef-
forts in the pharmaceutical industry to develop mixed
agonist-antagonist opiates as safer analgesics. Drugs
Neuron
204that emerged from this program, such as pentazocine
and buprenorphine, remain the least-addictive commer-
cially marketed opiates.
Modern Era
I came to Johns Hopkins for psychiatry residency in
1965 and, during the second year of residency, was ap-
pointed a full-time Assistant Professor of Pharmacology
while still a full-time psychiatry resident. At that time,
systems neuroscience was a dominant presence in the
Department of Physiology, directed by Vernon Mount-
castle. David Bodian, the Director of Anatomy and him-
self a distinguished neuroanatomist, had recruited nu-
merous neuroanatomists to his department. Neither
neurochemistry nor neuropharmacology existed at Hop-
kins. After I completed psychiatry residency in 1968 and
was promoted (Associate Professor, Pharmacology and
Psychiatry; 1970 Full Professor), Paul Talalay, Director
of Pharmacology, appointed new faculty in a nascent
‘‘division’’ of neuropharmacology. These included Mi-
chael Kuhar, my first graduate student, who did post-
doctoral training at Yale with George Aghajanian, and
Joseph Coyle, my first medical student trainee and sub-
sequently Research Associate with Julie Axelrod. Elliott
Richelson, a Hopkins medical student who had worked
with me and was subsequently an NIH Research Associ-
ate with Marshall Nirenberg, was for a few years a mem-
ber of our division.
Early research in my laboratory with Coyle and Kuhar
focused on neurotransmitter uptake. Axelrod had estab-
lished reuptake by sympathetic nerve endings of norepi-
nephrine as the mode of its synaptic activation in experi-
ments utilizing injections of radiolabeled norepinephrine
into rodents. To study transmitter uptake in vitro and
examine its kinetic properties, we sought to employ iso-
lated nerve endings, synaptosomes. However, synapto-
somes could only be prepared in sucrose solutions,
while an ionic environment was required for transmitter
uptake. As a medical student, Coyle devised a simple
solution to this dilemma, homogenizing the brain first
in hypertonic sucrose and then adding ionic buffers
with the sucrose protecting the synaptosomes from
degradation. This system permitted the evaluation of
numerous putative neurotransmitters, especially the
demonstration that amino acids that seemed to be
good candidates as neurotransmitters, glutamate, as-
partate, and glycine (in the spinal cord), possessed
high-affinity sodium-requiring uptake systems which
were not evident for ‘‘ordinary’’ amino acids (Logan
and Snyder, 1971). At the Lilly Research Laboratories,
David Wong adopted this crude synaptosomal prepara-
tion to screen drugs for selective inhibition of serotonin
versus norepinephrine uptake, permitting the discovery
of fluoxetine (Prozac) (Wong et al., 2005).
In 1973, utilizing simple reversible ligand-binding
techniques with crude brain membranes, we were able
to identify opiate receptors in the nervous system (Pert
and Snyder, 1973). We extended this finding to recep-
tors for numerous neurotransmitters by seeking drugs
with high affinity and selectivity for receptors and ob-
taining from our valued collaborators at the New Eng-
land Nuclear Corporation (now Perkin-Elmer) tritiated
versions of the drugs (Snyder, 2002). Such studies per-
mitted the demonstration that the relative potencies ofneuroleptics in blocking dopamine receptors predicts
their antipsychotic actions. Ligand binding permitted
clarification of anticholinergic sedative and hypotensive
side effects of neuroleptics and antidepressants. In his
own laboratory, Kuhar developed ligand-binding techni-
ques for autoradiography, permitting him to localize opi-
ate and other neurotransmitter receptors at a micro-
scopic level and to explain with reasonable precision
most of the therapeutic and adverse effects of opiates
(Young and Kuhar, 1979). Subsequently, in collaboration
with Henry Wagner, Chair of the Division of Nuclear
Medicine, he participated in the first imaging of neuro-
transmitter receptors in human brain by PET scanning,
technology subsequently employed with virtually all
neurotransmitter receptors (Wagner et al., 1983).
Coyle and his students employed receptor pharma-
cology to develop selective brain lesions. Following re-
ports that the rigid glutamate derivative kainate destroys
neurons by excitotoxicity, Coyle employed kainate le-
sions to destroy cell bodies in the caudate/putamen,
eliciting a model of Huntington’s disease (Coyle and
Schwarcz, 1976). He utilized similar kainate lesions in
the nucleus basalis of Meynert to establish that these
cells are the source of the major cholinergic innervation
of the cerebral cortex. In collaboration with Peter White-
house, Donald Price, and Mahlon DeLong in Neuropa-
thology and Neurology, he delineated the loss of the
cholinergic projection to the brain in Alzheimer’s disease
(Whitehouse et al., 1982). This work provided part of the
background for the subsequent use of cholinesterase
inhibitors in treating the memory loss of Alzheimer’s
disease.
Other important work on cholinergic transmission was
taking place in the laboratory of Daniel Drachman in the
Neurology Department. Drachman had long been in-
terested in the pathophysiology of myasthenia gravis.
As cholinesterase inhibitors were therapeutic, it was
assumed that something about cholinergic synapses
was abnormal. Once it was possible to measure nico-
tinic cholinergic receptors with radiolabeled a-bungaro-
toxin, Drachman and Douglas Fambrough in the Biology
Department at Hopkins demonstrated a profound
depletion of cholinergic receptors in muscle biopsies
of patients (Fambrough et al., 1973). At about the same
time, others showed that rodents that were immunized
with nicotinic cholinergic receptors develop symptoms
resembling myasthenia gravis. Drachman injected se-
rum of myasthenic patients into mice and reproduced
symptoms of the disease, establishing myasthenia gra-
vis as an autoimmune disease associated with degrada-
tion of cholinergic receptors (Toyka et al., 1977).
A major body of work in Neuropathology/Neurology
was carried out by Donald Price and Sangram Sisodia,
elucidating mechanisms of amyloid b-peptide formation
in Alzheimer’s disease. They employed elegantly de-
signed transgenic mice to establish how mutations of
the amyloid precursor protein and its processing en-
zymes elicit Alzheimer’s pathology (Price et al., 1998).
They employed similar strategies to clarify the role of
certain types of superoxide dismutase in amyotrophic
lateral sclerosis.
The Department of Biomedical Engineering has al-
ways housed distinguished neurophysiologists with
special expertise in auditory and vestibular studies.
Historical Perspective
205Figure 2. Primary Faculty of the Hopkins
Neuroscience Department, 2005
Lowest row (left to right): Dwight Bergles,
Gabriele Ronnett, Rudiger von der Heydt,
Solomon Snyder, Richard Huganir, Susanne
Boeke (administrator), Shanthini Sockana-
than. Middle row (left to right): Stephen
Hsiao, Jay Baraban, Ernst Niebur, Alex Ko-
lodkin, Min Li, Seth Blackshaw, C. Edward
Connor, Jonathan Pevsner. Upper row (left
to right): Mark Molliver, Alfredo Kirkwood,
King Wai-Yau, Nicholas Marsh-Armstrong,
Xinzhong Dong, David Linden, David Ginty.David Robinson pioneered in elucidating the vestibulo-
ocular reflex. The reflex maintains constancy of images
on the fovea of the retina as the head rotates. It does
this by causing the eyes to rotate at the same speed
as the head but in an opposite direction. In one classic
study, Robinson showed that this presumably ‘‘hard-
wired’’ reflex is modulated by experience, with the cere-
bellum critical for such modulation (Robinson, 1976). He
also showed that the cerebellum detects and repairs
dysmetria, a midjudgement of distances in motor
movements.
Murray Sachs, presently Director of the Department of
Biomedical Engineering, and Eric Young pioneered in
defining the code for detecting speech sounds, espe-
cially vowels. They showed that vowel perception is en-
coded by increased firing rates but that there is a dy-
namic range wherein the discharge rate of auditory
nerve fibers is capped (Sachs and Young, 1980).
Department of Neuroscience
Although our department was founded in 1980, we had
no independent laboratory space until 1983, when our
first recruits, Richard Mains and Elizabeth Eipper, joined
Kuhar, Coyle, and myself as full professors (Figure 2).
Mains and Eipper had done postdoctoral work with Ed-
ward Herbert at the University of Oregon, where they
discovered pro-opiomelanocortin, the protein precursor
of ACTH and b-endorphin. They then pioneered in the
biochemistry of neuropeptide processing (Eipper et al.,
1992). I felt it important to begin with senior faculty
who could share some of the administrative responsibil-
ities of a new department. Mains and Eipper rose to the
challenge, launching our graduate program. Besides de-
veloping a curriculum and recruiting students, they set
up a departmental seminar series and a substantial
number of graduate courses. When Kuhar left Hopkins
in 1985, we recruited Jay Baraban, a Yale M.D./Ph.D.,
who trained with George Aghajanian and, following psy-
chiatry residency at Columbia, did postdoctoral re-
search with me.
The next major impetus for departmental expansion
came with the launching by the Howard Hughes Medical
Institute (HHMI) of a neuroscience initiative. In those
days, HHMI operated by setting up ‘‘institutes’’ in vari-
ous disciplines at selected medical schools. The direc-
tors of such institutes recruited whoever they wished
(with approval of HHMI). In the mid-1980s, HHMI de-
cided to explore the neurosciences and ‘‘tapped’’ Har-vard/Massachusetts General Hospital, Columbia, the
University of California at San Francisco, and Johns
Hopkins as sites for a neuroscience enterprise. Dan Na-
thans, representing the already existing HHMI Molecular
Biology Institute, and myself, along with other faculty
advisors, in 1986 recruited the first HHMI neuroscience
faculty, Richard Huganir, King-Wai Yau, and Gary Yellen,
into the Neuroscience Department component of the
HHMI neuroscience program. Randall Reed and Jeremy
Nathans also joined the HHMI Neuroscience Institute
with primary appointments in Molecular Biology and Ge-
netics and secondary appointments in Neuroscience.
Subsequently, Yellen left Hopkins for Harvard. After
HHMI modified its procedure for developing new faculty,
adopting a national competition approach, David Ginty
and Alex Kolodkin, existing neuroscience faculty, were
appointed as HHMI members.
Besides constructing new space for its own laborato-
ries, HHMI provided a long-term loan of another
research floor to the medical school. Thus, at the
same time that the HHMI Neuroscience Institute was
launched, a group of neurophysiologists left the Physiol-
ogy Department to join the Neuroscience Department in
the HHMI-donated space. The group, designated the
Bard Laboratories of Neurophysiology and led by Ver-
non Mountcastle, included Kenneth Johnson, Gian Pog-
gio, and Steven Hsiao. At the same time, Mark Molliver
and Reinhard Grzanna, neuroanatomists in the Cell Biol-
ogy/Anatomy Department, joined the Neuroscience De-
partment in the space provided by HHMI. Subsequently,
more basic-science laboratory space was constructed,
enabling us to recruit additional faculty, including David
Linden, Paul Worley, Gabriele Ronnett, and Fabio Rupp
(Rupp subsequently left Hopkins to join a biotech com-
pany in California).
In the mid-1990s, a Mind/Brain Institute was estab-
lished on the College of Arts and Sciences campus of
Johns Hopkins, and the neurophysiology group moved
to this location. The additional space enabled the
Mind/Brain Institute to recruit new faculty, such as Stew-
art Hendry, Rudiger von der Heydt, Edward Connor,
Ernst Niebur, and Alfredo Kirkwood, all with primary ap-
pointments in the Neuroscience Department. The space
freed by the departure of neurophysiologists from the
medical campus permitted further faculty recruitment
with a focus in developmental neurobiology—David
Ginty, Alex Kolodkin, and Anirvan Ghosh. In 2000,
Drs. Mains and Eipper left Hopkins to launch a new
Neuron
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necticut and were replaced by Dwight Bergles and
Shanthini Sockanathan. In 2003, Min Li transferred his
primary appointment from Physiology to Neuroscience.
When Anirvan Ghosh departed in 2004 for an endowed
professorship at UCSD, we recruited Xinzhong Dong,
whose postdoctoral research at Caltech with David An-
derson uncovered the novel Mrg family of pain-mediat-
ing ion channels. Seth Blackshaw recently joined our
faculty elucidating differential gene expression in devel-
oping cell types in the retina and hypothalamus. Follow-
ing his doctoral research in my lab, he worked with Con-
stance Cepko at Harvard on retinal cell lineage. Primary
faculty housed in the Kennedy Krieger Institute on the
medical campus include Catherine Thompson, Jona-
than Pevsner, and Nicholas Marsh-Armstrong.
Typically, departmental development in medical
schools involves a dowry for a new chair to fill the de-
partment with faculty who then age so that the depart-
ment falters until a new chair is recruited. Various events,
many fortuitous, enabled us to avoid this dilemma. The
chronology described above reflects a means whereby
over 25 years our department was periodically renewed
with an influx of new, young faculty affording fresh per-
spectives.
Another unique feature of our department, at least
among basic-science departments at Hopkins, is our re-
cruitment of secondary faculty reflecting an abundance
of neuroscience research throughout the university.
Presently, we have 78 secondary and joint appoint-
ments, individuals who are not merely window dressing
but make major contributions to department teaching
and research.
There are too many current faculty to describe all their
research. Here I will focus on a limited number of exam-
ples that highlight some of the questions being investi-
gated as well as showcasing collaborative interactions.
Signaling
Signaling at the level of neurotransmitters and proteins
regulating receptor responses as well as intracellular
second messengers has constituted a major theme in
the department. In my own laboratory, the reversible li-
gand-binding technology that permitted the identifica-
tion of neurotransmitter receptors was extended to sec-
ond messengers. Thus, Jay Baraban and Paul Worley,
then fellows in my lab, used binding techniques to iden-
tify receptors for the second messenger inositol 1,4,5-
trisphosphate (IP3). At that time, the mid 1980s, we labo-
riously solubilized, then purified IP3 receptor protein.
Molecular cloning of proteins as large as IP3 receptors,
about 300 kDa, was in its infancy. To learn how the IP3
receptor might influence calcium conductance, we col-
laborated with Huganir, incorporating the receptors
into lipid vesicles labeled with radioactive calcium and
showed that IP3 released calcium, establishing that
the IP3 receptor protein contained the calcium ion chan-
nel as well as the IP3 recognition site (Ferris et al., 1989).
These studies would have been impossible were it not
for Huganir’s doctoral research with Ephraim Racker es-
tablishing that the nicotinic acetylcholine receptor pro-
tein contains the relevant sodium channel.
We became interested in novel neurotransmitters, es-
pecially gaseous molecules such as nitric oxide (NO)and carbon monoxide. Here again, conventional protein
purification was key. The only way to learn much about
an evanescent molecule such as nitric oxide would be
to find the enzyme that makes it, but efforts in numerous
laboratories had failed because NO synthase appeared
to be extraordinarily labile. Knowing that calcium was
somehow involved in NO formation, my M.D./Ph.D. stu-
dent David Bredt added calmodulin to crude enzyme
preparations, stabilizing the protein, facilitating its puri-
fication and cloning and explaining how neuronal depo-
larization can activate NO formation by causing calcium
to enter cells and bind to calmodulin (Bredt et al., 1991).
Soon, it was possible to establish that NO is a major neu-
rotransmitter of the autonomic nervous system as well
as regulating sexual and aggressive behavior in the
brain (Nelson et al., 1995). Since neurotransmitters
come in chemical classes, we looked for other gaseous
transmitter candidates and obtained compelling evi-
dence that carbon monoxide, derived from heme by
a neuronal form of heme oxygenase, is a coneurotrans-
mitter with NO mediating nonadrenergic-noncholinergic
neurotransmission in the autonomic nervous system.
Our interest in atypical transmitters led to studies
showing that the unnatural D-isomer of serine is a neuro-
modulator generated by glia and serving as an endoge-
nous ligand for the ‘‘glycine’’ site of NMDA receptors,
hence acting as a coagonist with glutamate at these re-
ceptors in the brain. Elucidation of D-serine as a trans-
mitter led to further collaborations with Huganir. We
showed that serine racemase, the enzyme that we dis-
covered to generate D-serine from L-serine, binds to
GRIP, a PDZ domain-containing protein discovered by
Huganir in collaboration with Paul Worley, which in-
teracts with AMPA-glutamate receptors. Synaptically
released glutamate activates AMPA receptors on glia
causing GRIP to bind to serine racemase and massively
activate its formation of D-serine (Kim et al., 2005).
Huganir has been a world leader in the regulation of
neurotransmitter receptor regulation by phosphoryla-
tion as well as by binding to receptor-interacting pro-
teins such as GRIP. In his early studies with Paul Green-
gard, Huganir showed how phosphorylation regulates
desensitization of nicotinic acetylcholine receptors,
with both serine and tyrosine phosphorylation playing
major roles (Huganir et al., 1986). He extended this
work to numerous receptors, including those for GABA
as well as NMDA and AMPA forms of glutamate recep-
tors. He then addressed the role of receptor phosphory-
lation in synaptic plasticity and memory. Abundant work
favored a role for phosphorylation of synaptic proteins in
synaptic plasticity, but there was no direct evidence. In
a tour-de-force, Huganir generated mice with knockin
mutations in selected phosphorylation sites of the
GluR1 subunit of AMPA receptors (Lee et al., 2003).
The mutant mice showed defects in long-term depres-
sion (LTD) and long-term potentiation (LTP) as well as
memory defects in spatial learning tasks. He also has
identified numerous proteins that regulate synaptic plas-
ticity (Ye et al., 2000; Dong et al., 1997).
David Linden, a cellular electrophysiologist, has col-
laborated extensively with Huganir and Worley in clarify-
ing molecular bases of LTD and LTP. Linden pioneered
models of cerebellar LTD in culture systems which re-
place stimulation of nerve fibers with bath application
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plasticity, such as synaptically driven changes in the in-
trinsic excitability of deep nuclei as well as LTD of the
climbing-fiber synapse (Hansel and Linden, 2000). In
collaboration with Huganir, Linden showed that phos-
phorylation of the GluR2 type of AMPA receptor is
required for cerebellar LTD (Chung et al., 2003). Thus,
LTD is absent from cultured cerebellar Purkinje cells of
mutant mice lacking GluR2 receptors and can be res-
cued by transfection with wild-type. Huganir had
showed that protein kinase C phosphorylation of ser-
ine-880 in the carboxyl-terminal PDZ ligand of GluR2 is
critical for plasticity of the receptors. Linden discovered
that transfecting the GluR2 null Purkinje cells with a mu-
tant that prevents PKC phosphorylation at serine-880
fails to rescue LTD.
Following postdoctoral training in my laboratory
where he identified IP3 receptors, Paul Worley teamed
up with Jay Baraban to identify a series of immediate
early genes that are upregulated by selective neuronal
activation. Worley then spent three years in the labora-
tory of Dan Nathans obtaining molecular biological ex-
pertise that enabled him to characterize these genes,
many of which have emerged as major regulators of syn-
aptic plasticity. One of the most important, identified in
collaboration with Huganir, is Homer, first described as
an immediate early gene whose protein product binds
selectively to metabotropic glutamate receptors (Brake-
man et al., 1997). In collaboration with David Linden,
Worley showed that Homer binds within its target pro-
teins to a novel proline-rich motif, the ‘‘Homer ligand,’’
enabling a Homer dimer to bring IP3 receptors and the
metabotropic glutamate receptors in proximity. This
process permits metabotropic glutamate neurotrans-
mission to influence IP3 release of calcium (Tu et al.,
1998). He subsequently showed that Homer can regu-
late calcium entry into cells as it cross links IP3 recep-
tors and TRP calcium channels in the plasma mem-
brane, explaining how IP3 receptors regulate calcium
entry (Yuan et al., 2003).
Sensory Transduction
Hopkins has a long tradition of sensory research.
Mountcastle’s pioneering work on the columnar organi-
zation of the brain was based on investigations of tactile
stimuli, a body of work carried forward by the late Ken-
neth Johnson and by Steve Hsiao. Hubel and Weisel
brought the columnar concept into studies of photo-
transduction. Auditory neurophysiology has long been
a strength, as described above in the research of Murray
Sachs and Eric Young. In recent years, molecular inves-
tigations of diverse senses, including vision, smell, and
pain perception, have been areas of intense activity.
Jeremy Nathans obtained his M.D./Ph.D. at Stanford.
Working independently in the laboratory of David Hog-
ness, he cloned the gene for rhodopsin and used this
as a template to identify the genes for color vision. He
then obtained blood samples of individuals suffering
from diverse forms of color blindness and elucidated
the molecular basis for the principal types of color blind-
ness. This body of work, published in two lead articles in
Science, revolutionized color-vision research (Nathans
et al., 1986a, 1986b). Nathans has continued to clarify
molecular bases of phototransduction and extendedhis investigations to a variety of diseases, in the process
discovering novel regulatory mechanisms. For instance,
he identified the gene underlying the vitelliform type
of macular dystrophy and showed that it defines a new
family of chloride ion channels, a study conducted in
collaboration with King-Wai Yau (Sun et al., 2002). A
long-term goal has been to find causes of macular
degeneration, a common form of blindness. Stargardt
macular dystrophy is a relatively rare genetic form of
this condition for which Nathans characterized a photo-
receptor cell-specific mutation in the ATP-binding trans-
porter gene (Sun et al., 2000).
King Wai-Yau has long been a pioneer in phototrans-
duction. He discovered the critical role of cyclic GMP in
phototransduction and then showed how cyclic GMP
and calcium work together (Haynes et al., 1986; Naka-
tani and Yau, 1988). Light produces a hyperpolarizing re-
sponse in rods by triggering a decrease in cyclic GMP
and thus closure of cyclic GMP-activated channels.
The closing of these channels leads to decreased cal-
cium levels in the rod outer segment, activating nega-
tive-feedback pathways to bring about light adaptation.
Recently, Yau discovered a novel population of photore-
ceptors that are neither rods nor cones and which en-
able light to synchronize circadian rhythms even in blind
animals and people. In collaboration with David Berson
at Brown University, he identified a small population of
retinal ganglion cells that express a novel pigment, mel-
anopsin (Hattar et al., 2002). The melanopsin-containing
ganglion cells project to the suprachiasmatic nucleus of
the hypothalamus, the central circadian pacemaker of
the brain, as well as to brain nuclei that regulate the pu-
pillary light reflexes that are maintained in blind animals.
Mice with genetic deletion of melanopsin display impair-
ments in light entrainment of circadian rhythms.
Yau also has been a leader in olfactory transduction.
About 12 years ago, he identified an unusual depolariz-
ing calcium-activated chloride current that is crucial for
olfactory transduction. Recently, he discovered a dra-
matic difference between G protein signaling in olfaction
and vision (Bhandawat et al., 2005). It has long been as-
sumed that a single G protein-coupled receptor acti-
vates vast numbers of G proteins, a phenomenon well
established for rod phototransduction. In contrast, fol-
lowing binding of odorants, their receptors have a very
low probability of activating even a single downstream
G molecule, because odorants remain in contact with re-
ceptors for less than a millisecond. It appears likely that
the model for olfaction is the norm for G protein signaling
and that the amplification scheme for phototransduction
is an exception.
Randy Reed has also pioneered in molecular ap-
proaches to olfaction. He cloned a unique odorant-bind-
ing protein as well as olfactory-selective G proteins, ad-
enylyl cyclase and cAMP-regulated ion channels. He has
elucidated promoters that determine the localization of
odorant receptors as well as the restrictive expression
in individual olfactory neurons of only single-odorant
receptors (Lewcock and Reed, 2004).
Michael Caterina is a Hopkins-trained M.D./Ph.D. who
did his thesis work with Peter Devreotes elucidating sig-
nal transduction by cyclic AMP in regulating aggregation
of the amoebae comprising slime molds. He then joined
David Julius at the University of California at San
Neuron
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for the active ingredient in hot peppers, capsaicin
(Caterina et al., 1997). This receptor, also called the va-
nilloid receptor (TRPV1), is a member of the TRP family
of plasma-membrane calcium channels discovered by
Craig Montell, a Hopkins Professor of Biochemistry
with a secondary appointment in Neuroscience (Montell
et al., 2002). At Hopkins, as a faculty member in Biolog-
ical Chemistry with a secondary appointment in Neuro-
science, Caterina has greatly extended his initial
findings. Mice with targeted deletion of TRPV1 demon-
strate major impairments in pain perception, while dele-
tion of a heat-selective channel alters heat perception
(Lee et al., 2005). Caterina cloned a family of related
ion channels, some of which respond to heat but not
to protons or capsaicin. Remarkably, there is a ‘‘cold’’
receptor in the family that is activated by menthol and
other ‘‘cold-eliciting’’ substances.
Sensory perception is a major focus of the systems
neuroscientists in the Mind/Brain Institute. The scientific
lineage of the group goes back to the approach devel-
oped by Vernon Mountcastle of correlating behavior of
awake, performing monkeys with the activity of individ-
ual neurons in the cerebral cortex. Mountcastle trained
the late Kenneth Johnson, former Director of the Mind/
Brain Institute, who in turn trained and collaborated
with Steven Hsiao. Hsiao and Johnson continued the
strategy initiated by Mountcastle of employing tactile
sensation as an entre´e to how the cerebral cortex inte-
grates sensory information. One focus has been an elu-
cidation of modality-specific attention, which allows us
to disregard sensory information when it is irrelevant
(e.g., the constant pressure of clothing on our bodies)
or highlight it when it is important (e.g., the spatial pat-
tern of pressure on the fingers when reading Braille).
Their research suggests that attention to touch depends
on increased synchronization between neurons in pri-
mary somatosensory cortex (Steinmetz et al., 2000), as
predicted in theories elaborated by Ernst Niebur (Niebur
et al., 2002). Other work focuses on higher-level somato-
sensory cortex and its role in three-dimensional-object
perception with the hand (Fitzgerald et al., 2004).
Rudiger von der Heydt and Ed Connor (another stu-
dent of Johnson’s) study object perception in the visual
system. Von der Heydt has shown how complex Gestalt
principles for inferring objects from multiple two- and
three-dimensional-contour cues are embodied by the
activity of neurons in primary and secondary visual cor-
tex (Peterhans and von der Heydt, 1991; Qiu and von der
Heydt, 2005). Connor focuses on higher-level visual cor-
tex, where objects are represented as configurations of
parts, by populations of neurons encoding the local ge-
ometry and relative positions of contour and surface
fragments (Brincat and Connor, 2004; Pasupathy and
Connor, 2002).
Developmental Neurobiology
Our department’s efforts in molecular approaches to de-
velopment have featured close interactions between
David Ginty, Alex Kolodkin, and, till he moved recently
to the University of California at San Diego, Anirvan
Ghosh. Both Ginty and Ghosh were postdoctoral fellows
with Michael Greenberg at Harvard. Kolodkin obtained
his postdoctoral training with Corey Goodman at theUniversity of California at Berkeley, where he discovered
the semaphorins, the first family of proteins that mediate
axonal pathfinding by repelling other neurons. Together
with Ginty, Kolodkin identified the first cell-surface sem-
aphorin receptor, neuropilin1 (Kolodkin et al., 1997). Ko-
lodkin then uncovered a novel, enzymatic regulation of
neuronal repulsion by isolating MICAL, a large cytosolic
axonal protein that binds to plexin-A, one of the sema-
phorin receptors, and is required for the ability of sema-
phorin 1A to repel axons (Terman et al., 2002). MICAL
has a flavoprotein monooxygenase domain, whose
integrity is required for axonal repulsion. Thus, an enzy-
matic oxidoreductase activity appears critical for repul-
sive neuronal guidance, which opens the way to enzyme
inhibitors as therapeutic agents.
David Ginty has been a leader in characterizing signal-
ing by nerve growth factor (NGF) and related neurotro-
phic growth factors. He was the first to show that vesic-
ular trafficking of the complex of NGF and its receptor
TrkA is responsible for retrograde NGF signaling from
distal axons to neuronal cell bodies (Riccio et al., 1997;
Ye et al., 2003). He observed that this retrograde sig-
naling requires CREB-dependent gene expression for
NGF-determined axon growth and neuronal survival
(Lonze et al., 2002). He recently illuminated how NGF
interacts with the related neurotrophin NT-3 (Kuruvilla
et al., 2004). NT-3 released from blood vessels enhances
the growth of axons as they move toward their ultimate
target field. In order for axons to reach their targets, they
must ‘‘decathect’’ NT-3. This is accomplished by NGF
augmenting the expression of the auxiliary NGF receptor
p75, which causes TrkA to become less responsive to
NT-3.
Another relationship of vasculature and neurotrophins
is evident in a Ginty-Kolodkin collaboration based on the
finding that neuropilin1 is also a receptor for vascu-
lar endothelial growth factor (VEGF). Utilizing genetic
knockin mice, the team showed that while sema-
phorin-neuropilin1 signaling mediates axon guidance,
development of the vasculature depends on VEGF-neu-
ropilin1 signaling, and formation of the heart requires
both types of signaling (Gu et al., 2003). Interestingly,
semaphorin signaling is also critical for vascular devel-
opment, but in a neuropilin1-independent manner in-
volving the divergent semaphorin receptor plexin D1
(Gu et al., 2005).
Clinically Relevant Neuroscience
Neuroscience research has prospered in clinical de-
partments at Hopkins, whose researchers possess sec-
ondary appointments in our department. Fundamental
molecular neuroscience with clinical relevance is exem-
plified in the work of Ted Dawson, Valina Dawson, and
Christopher Ross. Ted Dawson obtained his neurology
training at the University of Pennsylvania, where Valina
Dawson was a postdoctoral researcher. They subse-
quently did advanced postdoctoral work in my own lab-
oratory, following which they joined the Department of
Neurology with secondary appointments in Neurosci-
ence. The Dawsons worked with me soon after the clon-
ing of neuronal NO synthase. They discovered that NO
mediates neurotoxicity caused by glutamate-NMDA re-
ceptor stimulation. In their own laboratory, in collabora-
tion with our group, they showed that this neurotoxicity
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polymerase1 (PARP1) (Eliasson et al., 1997). PARP1 is
a DNA-repair enzyme which employs NAD as a sub-
strate. Overstimulation of PARP following neurotoxic in-
sults depletes NAD and then ATP so that cells die of en-
ergy deficit. They showed that PARP1-knockout mice
manifest up to an 80% protection from stroke damage.
They subsequently elucidated downstream aspects of
this pathway, identifying a novel caspase-independent
pathway of programmed cell death involving apopto-
sis-inducing factor (AIF) acting downstream of NO and
PARP1 (Yu et al., 2002).
The Dawsons have also clarified the pathophysiology
of Parkinson’s disease. Mutations in parkin, a ubiquitin-
3-ligase, cause a form of recessive Parkinson’s disease.
They discovered that S-nitrosylation of parkin impairs its
function, which provides a mechanism whereby cyto-
toxic insults, via NO, may lead to the common sporadic
form of Parkinson’s disease (Chung et al., 2004).
Christopher Ross obtained his M.D./Ph.D. at Cornell
with the late Donald Reis. After a Hopkins psychiatry
residency and further postdoctoral time in my own lab-
oratory, he joined the Psychiatry Department with sec-
ondary appointments in Neuroscience and Neurology.
He has focused on molecular features of neurodegener-
ative diseases, especially Huntington’s disease. For in-
stance, in collaboration with the Dawsons, Ross showed
that mutant huntingtin binds the transcriptional co-
activator CREB-binding protein, CBP (Nucifora et al.,
2001). In Huntington’s disease postmortem brain (as
well as Huntington’s disease transgenic mice and cell
culture models), CBP was depleted from its nuclear
localization and appeared instead in polyglutamine
aggregates. Overexpression of CBP rescued polyglut-
amine-induced neuronal toxicity. Thus, polyglutamines
in Huntington’s disease and related disorders damage
cells in part by interfering with CBP-regulated gene tran-
scription. In collaboration with the Dawsons, Ross has
also studied Parkinson’s disease. In one study, they
showed that parkin ubiquitinates synphilin-1, a protein
identified by Ross’ group as associated with a-synuclein
and present in the Lewy bodies of Parkinson’s disease
brain. Whereas ubiquitination normally leads to protein
degradation, the Dawson-Ross team found that the
ubiquitination of synphilin-1 occurs in a nonclassical,
proteasome-independent fashion, likely contributing to
Lewy body formation (Chung et al., 2001).
Recently, Ross has collaborated with our own labora-
tory in studies with Akira Sawa and Byoung Il-Bae show-
ing that the tumor suppressor p53 mediates cellular dys-
function and behavioral abnormalities in Huntington’s
disease (Bae et al., 2005). Overexpression of mutant
huntingtin upregulates nuclear p53 and its transcrip-
tional activity. Moreover, p53 levels are increased in
the brains of Huntington’s disease patients and trans-
genic Huntington’s mice. Pharmacologic or genetic
inhibition of p53 reduces cytotoxicity in Huntington’s
disease cells and neurobehavioral abnormalities of
transgenic Huntington’s mice.
Conclusions
Neuroscience, a long-time presence at Johns Hopkins,
was enhanced by the establishment in 1980 of a formal
departmental structure. The department structure hasfacilitated recruitment of a cadre of young, dynamic fac-
ulty as well as integration of neuroscience research
throughout the university. Our departmentally based
graduate program has generated talented investigators
who now populate universities nationwide. Intimate col-
legial relationships have spawned multiple collabora-
tions among basic and clinical neuroscientists leading
to numerous scientific advances.
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